Scarica l'app Stockscreener
1.09
2.68%
-0.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Ocugen Inc Borsa (OCGN) Ultime notizie
Ocugen Strengthens Leadership and Advisory Board as It Targets Three Biologics Filings in Three Years - MSN
CGTLive®’s Weekly Rewind – July 25, 2025 - CGTLive®
Ocugen Inc. Stock Analysis and ForecastFree Risk Assessment Services - PrintWeekIndia
What analysts say about Ocugen Inc. stockMarket-leading profit generation - Autocar Professional
What risks could impact Ocugen Inc. stock performanceRapidly growing investment returns - jammulinksnews.com
What drives Ocugen Inc. stock priceStrongest growth potential - Autocar Professional
When is the best time to buy Ocugen Inc. stockMarket-leading growth rates - jammulinksnews.com
First Patient Dosed in Phase 2/3 GARDian3 Trial of OCU410ST for Stargardt Disease - CGTLive®
Is Ocugen Inc. a good long term investmentSkyrocketing profit margins - jammulinksnews.com
Ocugen, Inc. Announces New Appointments to its Retina Scientific Advisory Board and Executive Leadership Team - VisionMonday.com
Ocugen announces appointments to retina scientific advisory board and executive leadership team - Ophthalmology Times
Ocugen Bets Big On Gene Therapy Despite Major Setbacks - Finimize
Ocugen, Inc. Announces New Appointments to Retina Scientific Adv - GuruFocus
Ocugen expands advisory board and leadership team for gene therapy push - Investing.com India
Ocugen, Inc. Strengthens Retina Scientific Advisory Board and Leadership Team to Advance Gene Therapy Development for Blindness Diseases - Quiver Quantitative
Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team - GlobeNewswire
Ocugen Assembles Elite Gene Therapy Team: 3 Top Retina Experts Join as Company Targets Triple BLA Filing - Stock Titan
Ocugen doses first subject in trial of modifier gene therapy candidate - Yahoo Finance
Ocugen Doses First Patient in Pivotal Trial for Stargardt Gene Therapy - MyChesCo
Ocugen Announces Q2 2025 Financial Results Call and Business Update - MSN
Ocugen’s Phase 1 Study on OCU200: A Potential Game-Changer for Diabetic Macular Edema - TipRanks
Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 - GuruFocus
Ocugen doses first patient in phase 2/3 Stargardt disease trial - Investing.com Australia
Ocugen doses first patient in phase 2/3 Stargardt disease trial By Investing.com - Investing.com South Africa
Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 - GlobeNewswire
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):